[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643612":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":36,"responsibleParty":52,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":72,"conditions":73,"keywords":25,"overallStatus":75,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PD-1+JAK1i","EXPERIMENTAL","PD-1+JAK1i (+AVD)",[13],"Drug: PD-1+JAK1i",{"label":15,"type":16,"description":17,"interventionNames":18},"PD-1","ACTIVE_COMPARATOR","PD-1 (+AVD)",[19],"Drug: PD-1",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","PD-1 inhibitor: 3 mg\u002Fkg, IV, D1, 22; JAK1i: 4mg\u002Fm2, PO, QD, D1-35;",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"PD-1 inhibitor: 3 mg\u002Fkg, IV, D1, 22;",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Shuhong Shen","CONTACT","18930830638","+86","shenshuhong@scmc.com.cn",[37],{"facility":38,"status":25,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Xuzhou Children's Hospital","Xuzhou","Jiangsu","221000","China","CN",{"type":45,"coordinates":46},"Point",[47,48],117.28386,34.20442,{"lat":48,"lon":47},[51],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},{"type":53,"investigatorFullName":31,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Chair of hematology oncology department of SCMC","100643612","phase-1-pd-1-antibody-and-jak1-inhibitor-for-newly-diagnosed-pediatric-hodgikins-lympoma-100643612",false,"NCT07641010","PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma","A Prospective, Multicenter, Randomized Controlled Clinical Study of Camrelizumab in Combination With Ivarmacitinib as First-line Treatment for Pediatric Classical Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Age 6-18 years, male or female;\n2. Histologically confirmed classic Hodgkin lymphoma;\n3. Newly diagnosed, previously untreated patients;\n4. Subjects must have at least one measurable lesion, defined as: a lymph node lesion with the longest diameter \\>1.5 cm on CT cross-sectional imaging; or an extranodal lesion with the longest diameter \\>1.0 cm;\n5. ECOG performance status (PS) 0-2;\n6. Life expectancy ≥3 months;\n7. All screening laboratory tests must be performed as required by the protocol and within 7 days prior to enrollment. The laboratory values obtained at screening must meet the following criteria:\n8. Hematology (without blood transfusion, G-CSF, or medication to correct abnormalities within 14 days prior to screening):\n\n   * Hemoglobin (Hb) ≥70 g\u002FL;\n   * Absolute neutrophil count (ANC) ≥0.5×10⁹\u002FL;\n   * Platelet count (PLT) ≥30×10⁹\u002FL;\n9. Biochemistry:\n\n   * Direct bilirubin (DBIL) \\\u003C2 × upper limit of normal (ULN);\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN;\n   * Serum creatinine clearance ≥40 mL\u002Fmin;\n10. The patient or his\u002Fher legal guardian has signed the informed consent form (ICF) and voluntarily agrees to participate in this study.\n\nExclusion Criteria:\n\n1. Histopathologically confirmed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL);\n2. Prior anti-tumor therapy for classic Hodgkin lymphoma (cHL);\n3. Patients with central nervous system (CNS) involvement by lymphoma;\n4. Inability to swallow oral medication, or any other factor affecting oral drug administration and absorption;\n5. Presence of any active, known, or suspected autoimmune disease (subjects who are in a stable condition and do not require systemic immunosuppressive therapy are permitted to enroll);\n6. Use of immunosuppressive agents, including systemic corticosteroids, within 14 days prior to study drug administration (use of ≤10 mg\u002Fday prednisone or equivalent is permitted);\n7. History of other malignancies within the past 5 years;\n8. Severe cardiac dysfunction with ejection fraction (EF) \\\u003C50%, or severe cardiac arrhythmia;\n9. Any arterial thromboembolic event within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack;\n10. Active hepatitis B or hepatitis C infection;\n11. History of stroke or intracranial hemorrhage within the past 6 months;\n12. Known history of human immunodeficiency virus (HIV) positivity.","ALL","6 Years","18 Years",{"count":66,"type":67},112,"ESTIMATED","INTERVENTIONAL",[70,71],"PHASE1","PHASE2","A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma",[74],"Hodgkin Lymphoma","NOT_YET_RECRUITING","2026-06-10",{"date":78,"type":79},"2026-06-11","ACTUAL",{"date":81,"type":67},"2026-06-30",{"date":83,"type":67},"2030-09-30",{"name":5,"class":6},1]